The Alzheimer’s Prevention Initiative Generation Program: study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer’s disease

Cited by (117)

Items 101–117 of 117

1. Genetically Enriched Clinical Trials for Precision Development of Noncancer Therapeutics: A Scoping Review
   Benoît Delabays, Chiara De Paoli, Andrea Miller-Nesbitt, Vincent Mooser · 2024 · The Annual Review of Pharmacology and Toxicology
2. APOE Missense Variant R145C is Associated with Increased Alzheimer's Disease Risk in African Ancestry Individuals with the APOE Ε3/Ε4 Genotype
   Yann Le Guen, Michaël E. Belloy, Sarah J. Eger, Annabel W. Chen, Gabriel Kennedy, Timothy A. Thornton, Lindsay A. Farrer, Valerio Napolioni, Zihuai He, Michael D. Greicius · 2021 · SSRN Electronic Journal
3. Cognition
   Richard Young · 2021 · Wiley eBooks
4. Génétique de la maladie d’Alzheimer et des maladies apparentées : qu’en sait-on en 2022 ?
   Maïté Formaglio, Isabelle Le Ber, David Wallon · 2022 · La Presse Médicale Formation
5. Antiamyloid therapy of Alzheimer’s disease: origins, current state and prospects of development
   Sergey V. Vorobev, А. Yu. Emelin, S. N. Yanishevskij, Elena V. Kostina, Anna A. Galaeva · 2022 · Neurology Bulletin
6. Noninfectious Disease Vaccines
   Daniel E. Speiser, Aadil El-Turabi, Martin F. Bachmann · 2023 · Elsevier eBooks
7. Chapter 43. Agents for Neurocognitive Disorders
   Gayle M. Ayers, Frank W. Brown · 2024 · American Psychiatric Association Publishing eBooks
8. Pharmacotherapy of Alzheimer's disease: A thorny road to success
   Nurul Husna Ibrahim, Jaya Kumar, Wael M.Y. Mohamed · 2024 · Elsevier eBooks
9. Feasibility and acceptability of remote APOE-genotyping among research volunteers of an online recruitment registry (The Dutch Brain Research Registry)
   Lisa Waterink, Sven J. van der Lee, Dionne M. Nijland, F I van der Zee, Leonie N.C. Visser, Yolande A.L. Pijnenburg, Sietske A.M. Sikkes, Wiesje M. van der Flier, Marissa Deborah Zwan · 2025 · The Journal of Prevention of Alzheimer s Disease
10. Accounting for white matter uptake improves between tracer agreement in amyloid PET
    Yinghua Chen, Hillary D. Protas, Ji Luo, Shan Li, Javad Sohankar, Chen‐Ray Pan, Valentina Ghisays, Wendy Lee, Teresa Wu, Ding‐Geng Chen et al. · 2025 · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
11. Apoe genotype knowledge and its impact on cognitive beliefs and performance
    Sarah J. Barber, Meenakshi Menon, Katherine J. Shoemaker, Mara Mather, Jessica B. S. Langbaum, Jason H. Karlawish · 2025 · Aging Neuropsychology and Cognition
12. Additional file 1 of Dementia risk communication. A user manual for Brain Health Services—part 3 of 6
    Leonie N.C. Visser, Carolina Minguillón, Sánchez-Benavides, Gonzalo, Abramowicz, Marc, Altomare, Daniele, Karine Fauria, Giovanni Battista Frisoni, Jean Georges, Federica Ribaldi, Philip Scheltens et al. · 2021 · Figshare
13. Additional file 1 of Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease
    Angelika Caputo, Amy Racine, Inès Paule, Pierre N. Tariot, Langbaum, Jessica B., Neva Coello, Riviere, Marie-Emmanuelle, J. Michael Ryan, Lopez, Cristina Lopez, Ana Graf · 2023 · Figshare
14. Beta-Secretase Inhibitors
    Justyna A. Dobrowolska Zakaria, Robert J. Vassar · 2026 · Topics in medicinal chemistry
15. Peptide vaccination for Alzheimer's disease: Immunological foundations, therapeutic potential, and translational barriers
    Haoteng Chen, Y Y Lin, DeZhi Kang, Tong Zhao · 2026 · Journal of Alzheimer s Disease Reports
16. Enzyme−Targeted Therapeutics for Neurological Disorders
    Leonardo Massignan, Kanduru Lokesh, Sara Ziadat, David Uehling, Donald Fredric Weaver, Mark A. Reed · 2026 · Journal of Medicinal Chemistry
17. BindingDB Entry 50014915: Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor.
    BindingDB · 2023 · UC San Diego